PATENT CLAIM ANALYSIS

Application Number: 15760076
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["424", "450000"]

Abstract:
The disclosure provides pharmaceutical compositions and method of using the compositions, wherein the compositions comprise liposomes that contain two or more anticancer drugs. In various embodiments the components of the liposomes can include a) a phospholipid, b) a pegylated lipid, c) an aqueous core, and d) at least one covalently-linked drug-conjugated lipid, an encapsulated drug, or a combination thereof, wherein the drug of the lipid-drug conjugate, encapsulated drug, or both, are anticancer drugs.

Claim (Index 6):
The liposome of  claim 3  wherein the HDAC inhibitor is rocilinostat (ACY-1215) or vorinostat.

Metadata:
- Claim Count in Document: 36.0
- Percentile: 90.0
- Lexical Diversity: 1.71154
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14765620', '13224399', '13581274', '15495474', '15301020']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7448445912334068
- 35 USC 102 Novelty (BERT): 0.5459394865189718
- Combined Prediction Score: 0.7249540807619633
- Mean Citation Score: 351.677094
- Max Citation Score: 387.1188
- Similarity Product: 266.6536045064449

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test